Malaysia coronavirus testing kits market is expected to grow at a significant rate during the forecast period, 2024-2028. With the sudden outbreak and spread of pandemic COVID-19, growing awareness about preventive healthcare practices, and increasing healthcare expenditure by the government are the primary factors driving the demand for the Malaysia Coronavirus Testing Kits Market for the next five years. To combat the rise in number of cases and variants of coronavirus, leading authorities and healthcare facilities are requesting to conduct tests for treatment of COVID-19. The Malaysia coronavirus testing kits market is expected to witness significant growth in the coming years due to the increasing number of COVID-19 cases in the country. According to the Worldometer website, as of March 24, 2023, Malaysia has reported over 2.7 million cases and 27,000 deaths due to the virus.
Coronavirus testing kits are helpful in recognizing the affected individuals who can further take necessary treatment from medical centres. Increase in the need to identify the hotspot zones and making the affected patients to stay in isolated areas either in healthcare or residential spaces is expected to foster the coronavirus testing kits market. To control the spread of coronavirus, the number of tests conducted daily are increased to get clear picture of the exact situation of the pandemic.
The antigen rapid test kits are the most commonly used testing kits in Malaysia. These testing kits are designed to detect the presence of the virus in a sample within 15 to 30 minutes. They are relatively affordable and easy to use, which has made them popular among healthcare providers. The RT-PCR test kits are also widely used in Malaysia. These testing kits are more accurate than antigen rapid test kits and can detect even small amounts of the virus in a sample. However, they are more expensive and require specialized equipment to run the tests, which has made them less accessible than antigen rapid test kits.
Rising Prevalence of Novel Corona Virus Strains
According to Ministry of Health (MOH) in Malaysia, there were 5,251 COVID-19 cases including 86 deaths and 2,967 cases of recovery were found in April 2020.
Technological Advancement
According to Statista, the revenue in the healthcare segment in Malaysia is projected to reach USD105.90 million in 2022 and is expected to hit around 20.4% by 2027
Government Initiatives
The Government of Malaysia enforced a Movement Control Order in starting pandemic to break the chain of COVID-19. The media actively spread the stay-home policy.
Additionally, the Malaysian government has made significant investments in expanding testing capabilities, with a goal of testing 150,000 people per day by the end of 2021. To achieve this, the government has established public-private partnerships with local manufacturers to increase the production of testing kits and has also imported testing kits from other countries to meet demand. This in turn, responsible for the growth of Malaysia Coronavirus Testing Market.
Recent Developments
The Malaysian government has been working to increase testing capacity by ramping up production of testing kits. In November 2020, Malaysia’s Ministry of Health (MOH) announced that it had developed its own COVID-19 test kit, known as the MyEG Covid-19 rapid testing kit. The kit was developed in collaboration with a local company, Gano Excel Industries, and has since been approved by the MOH for use in Malaysia. The MyEG Covid-19 rapid testing kit is a lateral flow immunoassay that detects the presence of antibodies in a person’s blood. The kit can produce results in just 15 minutes and has a reported accuracy rate of 94.2%. The kit is also affordable, with a cost of RM39 (approximately USD 9) per test.
The development of the MyEG Covid-19 rapid testing kit has helped to increase Malaysia’s testing capacity and reduce the country’s dependence on imported test kits. The MOH has also approved several other rapid testing kits for use in Malaysia, including the Antigen Rapid Test Kit (ART) and the Abbott Panbio COVID-19 antigen rapid test and participate to propel the growth of Malaysia Coronavirus Testing Kits Market. In addition to the development of local testing kits, Malaysia has also been working to increase the availability of testing through partnerships with private companies. In December 2020, the MOH announced that it had partnered with four private laboratories to provide COVID-19 testing services. The partnership allowed private laboratories to offer PCR tests at a lower cost, making testing more accessible to the public. Thereby, led to the development of Malaysia Coronavirus Testing Kits Market.
Market Segmentation
The Malaysia coronavirus testing kits market is segmented by type of test, use, full test time, technology, specimen type, mobility and end user, regional distribution, and competitional landscape. Based on type of test, the market is further segmented into molecular and serological. Based on use, the market is further segmented into multiple test and single test. Based on full test time, the market is further segmented into 5 Hours-12 Hours, 1 Hours- 5 Hours, 15-60 Minutes, less than 15 Minutes, 12 Hours-24 Hours, More Than 1 Day. Based on technology, the market is bifurcated into RT-PCR, and Rapid Diagnostic. Based on specimen type, the market is further segmented into Nasopharyngeal Specimen, Oropharyngeal Specimen, Blood, Sputum, and Others. Based on mobility, the market is further segmented into Stationary, and Mobile. Based on End User, the market is further segmented into Public Health Labs, Hospitals, Private or Commercial Laboratories, and Others.
Market Players
Medical Innovation Ventures Sdn. Bhd. (Mediven), Sengenics Sdn. Bhd., Top Biotech Sdn Bhd, Quidel Corporation Malaysia, Roche (Malaysia) Sdn. Bhd., Abbott Laboratories (M) Sdn. Bhd., Cellex, Inc Malaysia, SD Biosensor, Inc Malaysia, etc. are some of the leading companies operating in the market.
Attribute | Details |
Base Year | 2022 |
Historical Years | 2018 – 2022 |
Estimated Year | 2023E |
Forecast Period | 2024F – 2028F |
Quantitative Units | Revenue in USD Million, Volume in Units and CAGR for 2018-2022 and 2023E-2028F |
Report Coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered | · Type of Test · Use · Full Test Time · Technology · Specimen Type · Mobility · End User |
Region Scope | East Coast Region, Southern Region, Northern Region, East Region, Central Region |
Key Companies Profiled | Medical Innovation Ventures Sdn. Bhd. (Mediven), Sengenics Sdn. Bhd., Top Biotech Sdn Bhd, Quidel Corporation Malaysia, Roche (Malaysia) Sdn. Bhd., Abbott Laboratories (M) Sdn. Bhd., Cellex, Inc Malaysia, SD Biosensor, Inc Malaysia. |
Customization Scope | 10% free report customization with purchase. Addition or alteration to regional & segment scope. |
Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |